Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 13/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PDE5A | O76074 | 6/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.82 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.79 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868573 | 0.92 | ABCG2 (1.00) | ABCG2MEN1KMT2APDE5AALDH1A1 | |
| SCHEMBL14262835 | 0.90 | ABCG2 (0.82) | ABCG2MEN1KMT2APDE5AALDH1A1 | |
| SCHEMBL412953 | 0.90 | TGFBR1 (1.00) | ABCG2MEN1KMT2APDE5AALDH1A1 | |
| SCHEMBL31061048 | 0.90 | TGFBR1 (1.00) | ABCG2MEN1KMT2APDE5AALDH1A1 | |
| SCHEMBL7434986 | 0.90 | ALDH1A1 (1.00) | ABCG2MEN1KMT2APDE5AALDH1A1 | |
| SCHEMBL5531993 | 0.89 | ABCG2 (0.89) | ABCG2MEN1KMT2APDE5AALDH1A1 | |
| SCHEMBL4867505 | 0.89 | ABCG2 (1.00) | ABCG2MEN1KMT2APDE5ATGFBR1 | |
| SCHEMBL8095812 | 0.89 | ABCG2 (1.00) | ABCG2MEN1KMT2APDE5AALDH1A1 | |
| SCHEMBL1061916 | 0.89 | ABCG2 (1.00) | ABCG2MEN1KMT2APDE5AALDH1A1 | |
| SCHEMBL3460305 | 0.88 | ALDH1A1 (0.94) | ABCG2MEN1KMT2APDE5AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | claimed |
| JP-2008526734-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | claimed |
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | claimed |
| WO-2007047579-A2 | A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-8936840-B2 | Retardation film, polarizing plate, liquid crystal display device, and compound | Konica Minolta, Inc. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-8936840-B2 | Retardation film, polarizing plate, liquid crystal display device, and compound | Konica Minolta, Inc. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| EP-1789074-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | ABCG2 3042/4885MEN1 4790/4885KMT2A 1061/4885 |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, IDE, CTSC | ABCG2 713/4885MEN1 3779/4885KMT2A 4519/4885 |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | GPR119, GCKR, GLP1R | ABCG2 207/4885MEN1 3837/4885KMT2A 1662/4885 |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, EPOR, HBB | ABCG2 336/4885MEN1 3792/4885KMT2A 4560/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | ABCG2 2822/4885MEN1 4770/4885KMT2A 1377/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | ABCG2 3042/4885MEN1 4790/4885KMT2A 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.